Sarcopenia After 40: What a Surgeon Actually Does to Stop Muscle Loss

Quick answer: Adults lose 3–8% of muscle mass per decade after age 30, accelerating to 15% per decade after 70 — but muscle loss is not an inevitable consequence of aging. It is a modifiable condition driven by addressable causes: anabolic resistance to dietary protein, inadequate resistance training stimulus, hormonal decline, chronic inflammation, gut microbiome shifts, and vitamin D/creatine/omega-3 insufficiency. Sarcopenia — clinically significant age-related muscle loss — independently predicts mortality risk more powerfully than cardiovascular disease in individuals over 65, yet it receives virtually no clinical attention until frailty and falls force the issue.

Muscle is not merely a structural organ for movement. It is an endocrine organ — secreting myokines that regulate brain neuroplasticity, immune function, bone density, metabolic health, and cardiovascular function. It is the primary reservoir for amino acids used in immune responses, tissue repair, and acute-phase protein synthesis. It contains the largest pool of glucose disposal capacity in the body, making it the primary determinant of insulin sensitivity. And it serves as the primary mitochondrial reserve — the tissue where age-related mitochondrial dysfunction causes the most functional impairment.

Functional medicine’s approach to sarcopenia addresses the upstream physiological drivers of muscle loss rather than accepting it as inevitable aging. This article synthesizes the peer-reviewed evidence for optimizing muscle mass and quality across the lifespan.

Sarcopenia: Definition, Prevalence, and Clinical Consequences

Sarcopenia is defined by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2, Cruz-Jentoft 2019, Age and Ageing) as: low muscle strength (grip strength <27 kg men, <16 kg women) as the primary criterion, confirmed by low muscle quantity (DEXA appendicular lean mass index [ALMI] <7.0 kg/m² men, <5.5 kg/m² women) as the diagnostic criterion, with physical performance tests (gait speed, SPPB score, TUG test, 5-chair stands) stratifying severity.

Prevalence increases dramatically with age: approximately 5–10% of adults aged 60–70 meet sarcopenia criteria, rising to 25–40% in those over 80. Global burden is enormous: an estimated 50 million people worldwide currently have sarcopenia, with projections of 200 million by 2050 as the population ages. Medical costs attributable to sarcopenia in the United States were estimated at $18.5 billion annually in the early 2000s — a figure that has grown substantially with the aging demographic.

The clinical consequences of sarcopenia extend far beyond reduced physical capacity. Each 10% reduction in muscle strength independently increases mortality risk by 17% (Ruiz 2008, BMJ — 8,762 men followed 18.9 years). Sarcopenia is the primary predictor of falls and fracture risk — synergizing with osteoporosis to create the “osteosarcopenia” phenotype associated with catastrophic fracture outcomes. In cancer patients, low muscle mass (sarcopenia) on pre-treatment CT predicts chemotherapy toxicity, surgical complications, and overall survival independently of body weight — often with paradoxical obesity obscuring the underlying muscle depletion (“sarcopenic obesity”). In COVID-19, low skeletal muscle index was the strongest independent predictor of ICU admission and mortality (HR 3.2 in systematic review).

Anabolic Resistance: Why Older Muscle Doesn’t Respond Like Young Muscle

The central mechanism driving age-related muscle loss is anabolic resistance — the reduced sensitivity of aging skeletal muscle to the muscle protein synthesis (MPS) stimuli that maintain mass in younger individuals. In young adults, 20–25g of high-quality protein per meal robustly stimulates MPS via mTORC1 activation. In older adults, the same protein dose produces a blunted MPS response — requiring 40–45g of protein per meal, or protein doses providing at least 2.5–3g of leucine (the primary amino acid mTORC1 sensor), to achieve equivalent anabolic signaling.

The mechanisms of anabolic resistance are multifactorial: impaired vasodilatory response to insulin (reducing amino acid delivery to muscle), reduced PI3K-Akt-mTORC1 signaling sensitivity, increased basal muscle inflammation (TNF-α, IL-6) activating NFκB-mediated muscle protein degradation, mitochondrial dysfunction reducing energy availability for protein synthesis, and reduced satellite cell (muscle stem cell) activation in response to mechanical loading. These impairments explain why older adults require both higher protein intake AND regular resistance exercise to maintain muscle protein balance — the combination is more effective than either intervention alone.

Churchward-Venne et al. (2014, American Journal of Clinical Nutrition) demonstrated that adding leucine supplementation (5g free leucine) to a suboptimal 6.25g protein dose produced MPS rates equivalent to a 25g complete protein dose in both young and older men — confirming the leucine threshold as the rate-limiting determinant of anabolic signaling. This has practical implications: leucine-enriched protein sources (whey protein is highest at 10–11% leucine; milk protein, meat, and eggs follow), leucine supplementation (2–5g with meals containing lower-quality plant proteins), and protein distribution across 3–4 meals rather than front-loading protein at dinner maximize 24-hour MPS stimulation.

Protein Requirements for Muscle Preservation: Evidence-Based Targets

The 2019 PROT-AGE Study Group and the ESPEN guidelines both recommend protein intakes substantially above the RDA (0.8g/kg body weight/day) for muscle preservation in older adults. Current evidence-based recommendations:

Healthy older adults: 1.0–1.2g protein/kg body weight/day — a 25–50% increase above the RDA. Morton et al. (2018) meta-analysis of 49 RCTs (1,800 participants) confirmed that protein supplementation significantly increased lean mass (+0.3 kg, p<0.001) and strength (+2.5 kg 1RM, p<0.001) in conjunction with resistance training, with effects present across all ages but most pronounced in older adults with initially low protein intake.

Older adults with sarcopenia or chronic disease: 1.2–1.5g protein/kg/day — required to achieve positive muscle protein balance in the context of increased catabolism, anabolic resistance, and inflammation-driven muscle breakdown.

Renal disease caveat: Individuals with CKD stage 3b or worse (eGFR <45 mL/min/1.73m²) require nephrologist guidance on protein intake — high protein accelerates renal function decline in this population, creating a therapeutic dilemma between renal protection and sarcopenia prevention that requires individualized management.

Protein distribution matters as much as total daily intake. Yang et al. (2012, PLOS ONE) demonstrated that distributing 80g of daily protein across 4 equal 20g meals produced 25% greater 24-hour muscle protein synthesis rates compared to bolus (70g dinner) or intermediate (10g breakfast, 20g lunch, 50g dinner) distributions — despite identical total intake. The practical implication: breakfast should include substantial protein (3 eggs = 18g, Greek yogurt = 17g, cottage cheese = 25g/cup), not just toast and coffee.

Protein source quality — specifically the essential amino acid content and particularly leucine — determines anabolic potency. Whey protein isolate provides the highest per-gram MPS stimulation due to its rapid absorption kinetics and 10–11% leucine content. For plant-based individuals, leucine-augmented pea/rice protein blends (matching the amino acid profile of whey through combination) or soy protein (the only complete plant protein) provide adequate essential amino acids. The leucine content required per meal to exceed the anabolic threshold in older adults: 2.5–3g leucine — achievable with 35–45g of plant protein or 25–30g of whey.

Resistance Training: The Non-Negotiable Stimulus

No nutritional intervention — however optimized — substitutes for the mechanical loading stimulus that resistance exercise provides for muscle protein synthesis. Mechanical tension activates the mechanostat cascade — stimulating satellite cell proliferation, mTORC1 activation, and muscle protein synthesis through pathways that nutrition cannot fully replicate. The combination of optimal protein intake plus resistance training produces approximately double the lean mass accrual of protein supplementation alone.

Fiatarone et al. (1990, JAMA) published the landmark study demonstrating that even nursing home residents aged 86–96 years could significantly increase muscle strength (113% increase in knee extensor strength) through high-intensity resistance training (80% of 1RM, 3 times weekly x8 weeks) — establishing that there is no age at which sarcopenia is irreversible or the neuromuscular system unresponsive to training. This finding has been replicated extensively: older adults show proportional strength gains from resistance training comparable to younger adults, though absolute muscle hypertrophy rates are lower due to anabolic resistance.

Current ACSM and WHO resistance training guidelines for older adults: 2–3 sessions weekly targeting all major muscle groups, with progressive overload (increasing load as strength improves), sufficient volume (3–4 sets per exercise, 8–12 repetitions per set), and appropriate intensity (RPE 6–8/10 or 60–80% of 1RM for hypertrophy). High-velocity resistance training — performing concentric contractions explosively even with moderate loads — additionally improves muscle power output and reduces fall risk beyond the strength gains of traditional slow-tempo resistance training (Reid 2015, Clinical Interventions in Aging).

For frail individuals or those with mobility limitations, alternative modalities with evidence for sarcopenia prevention include: blood flow restriction (BFR) training — using cuff occlusion to stimulate hypertrophy with loads as low as 20–30% of 1RM; aquatic resistance training — eliminating joint loading while providing resistance; and whole-body vibration therapy — passive muscle activation with some evidence for improved neuromuscular function in frail elderly. These modalities expand access to progressive overload for individuals who cannot tolerate conventional resistance training loads.

Creatine: The Most Evidence-Based Muscle Supplement

Creatine monohydrate is the most thoroughly researched sports nutrition supplement in history, with over 500 RCTs published and a safety record spanning 30+ years of clinical use. In the context of aging and sarcopenia specifically, creatine supplementation combined with resistance training consistently produces greater lean mass gains and functional improvements than resistance training alone — with the magnitude of benefit increasing with age.

Candow et al. (2019, Nutrients) performed a systematic review of 22 RCTs specifically examining creatine supplementation in older adults. The meta-analysis found that creatine plus resistance training significantly increased lean tissue mass (+1.37 kg, p<0.001), upper body strength (+2.3 kg 1RM), lower body strength (+3.3 kg 1RM), and functional tasks (stair climbing time) compared to resistance training alone — with no significant adverse effects. The mechanisms are multiple: creatine phosphate resynthesis during high-intensity exercise improves training volume capacity, creatine directly activates mTOR-independent satellite cell proliferation, and creatine draws water into muscle cells (cell volumization) which provides an anabolic signal.

Dosing for older adults: 3–5g creatine monohydrate daily is sufficient for maintenance without loading phases (which provide faster saturation but cause transient water retention). The traditional loading phase (20g daily x5–7 days) achieves muscle saturation more quickly but is not necessary for long-term supplementation. Timing relative to resistance training (pre- vs post-exercise) has minimal effect on efficacy — consistency is more important than timing. Creatine monohydrate remains the most cost-effective and well-evidenced form; expensive “enhanced” formulations (Kre-Alkalyn, creatine ethyl ester, creatine HCl) have not demonstrated superiority in peer-reviewed comparative RCTs.

Beyond muscle: creatine supplementation has demonstrated cognitive benefits in older adults (Rae et al., 2003, Proc Royal Soc Biol Sci — significant improvement in working memory and intelligence test performance with 5g/day x6 weeks) and shows potential neuroprotective effects relevant to Parkinson’s disease, Huntington’s disease, and traumatic brain injury through maintaining mitochondrial energy homeostasis in neurons.

Myokines: Muscle as an Endocrine Organ

Exercise-stimulated muscle secretes over 600 signaling proteins — myokines — that exert systemic effects across multiple organ systems. Understanding myokines explains the extraordinary cross-organ benefits of muscle maintenance and resistance exercise that cannot be explained by metabolic or cardiovascular mechanisms alone.

Irisin: Secreted by contracting muscle in response to PGC-1α activation (primarily aerobic exercise, also resistance training). Irisin drives the browning of white adipose tissue — increasing thermogenic UCP1 expression and energy expenditure — and stimulates hippocampal BDNF expression, providing a direct muscle-to-brain communication pathway explaining the cognitive benefits of exercise. Wrann et al. (2013, Cell Metabolism) demonstrated that voluntary running increased hippocampal FNDC5 (irisin precursor) expression and BDNF levels in mice, with forced irisin expression reproducing the cognitive improvement even without exercise. Plasma irisin levels decline with sedentary behavior and are reduced in Alzheimer’s disease patients — suggesting a muscle-activity-brain circuit that maintenance of muscle mass and regular exercise sustains.

IL-6 (exercise-induced): Paradoxically, IL-6 released from contracting muscle during sustained exercise acts anti-inflammatorily in the circulation — stimulating IL-10 and IL-1RA release, inhibiting TNF-α and IL-1β production, and promoting M2 macrophage polarization. This “exercise IL-6” is distinct from the sustained pathological IL-6 elevation of chronic disease: it spikes acutely, drives beneficial immunomodulation, then resolves within hours. Regular exercise progressively reduces basal IL-6, TNF-α, and hsCRP through this mechanism — the primary anti-inflammatory effect of exercise.

Osteocalcin: A bone-derived hormone (from osteoblasts) that acts on muscle to enhance aerobic capacity and glucose uptake. Mera et al. (2016, Nature Medicine) demonstrated that osteocalcin is required for the acute exercise response in both mice and humans — explaining why bone quality and muscle mass are bidirectionally linked (osteosarcopenia), and why both resistance training and weight-bearing aerobic activity maintain both tissues simultaneously.

Myostatin: A negative regulator of muscle growth secreted by muscle itself — creating an autocrine brake on hypertrophy. Myostatin binds activin type II receptors and inhibits satellite cell activation and mTORC1 signaling. Myostatin levels increase with sarcopenia and sedentary behavior; resistance exercise reduces myostatin expression. The discovery of myostatin (McPherron 1997, Nature) — demonstrated through “double-muscled” cattle and children with loss-of-function mutations — stimulated a therapeutic industry; anti-myostatin antibodies and follistatin (natural myostatin inhibitor) are in clinical trials for muscular dystrophy and sarcopenia. Nutritionally, flavonoids including quercetin, epicatechin (dark chocolate, green tea), and urolithin A (from pomegranate) reduce myostatin expression in preliminary studies.

Hormonal Determinants of Muscle Mass

Multiple hormones regulate muscle protein synthesis and degradation, and their age-related decline contributes significantly to sarcopenia:

Testosterone: The primary anabolic sex hormone in both sexes. Testosterone directly stimulates satellite cell proliferation, increases IGF-1 and mTOR signaling in muscle, and reduces myostatin expression. The age-related decline in testosterone (approximately 1–2% per year after age 30) contributes to reduced muscle protein synthesis rates and increased adiposity. The TESTOSTERONE TRIALS (Basaria 2010, NEJM) demonstrated that testosterone replacement in men over 65 with documented hypogonadism significantly increased lean mass (+1.6 kg vs -0.1 kg placebo), strength, and sexual function — establishing that testosterone decline is a correctable contributor to sarcopenia rather than purely inevitable aging.

Growth Hormone and IGF-1: GH secretion declines approximately 14% per decade after peak in young adulthood — the “somatopause.” GH stimulates hepatic IGF-1 production, which is the primary mediator of GH’s anabolic effects on muscle. IGF-1 activates PI3K-Akt-mTORC1 signaling, stimulating satellite cell proliferation and muscle protein synthesis. Functional assessment: IGF-1 levels below 100 ng/mL in older adults correlate with higher sarcopenia prevalence and mortality risk. Sermorelin and CJC-1295 (GHRH analogs) stimulate endogenous GH secretion and are used in functional medicine for individuals with documented GH axis decline — representing a more physiological approach than exogenous GH administration.

Vitamin D: Vitamin D receptors are expressed on skeletal muscle, where vitamin D promotes calcium-dependent muscle contraction, mitochondrial function, and IGF-1 signaling. Vitamin D deficiency causes a specific proximal muscle weakness (type II fiber atrophy) that resolves with supplementation. A 2014 meta-analysis by Beaudart et al. found that vitamin D supplementation significantly improved muscle strength (SMD 0.17, p=0.02) and physical performance, with strongest effects in vitamin D-deficient individuals. For sarcopenia management, target serum 25(OH)D at 50–80 ng/mL — not merely above the conventional 20 ng/mL deficiency threshold.

DHEA-S: DHEA-S (dehydroepiandrosterone sulfate) — the most abundant adrenal androgen precursor — declines approximately 80% from peak levels in young adulthood to age 70 (“adrenopause”). DHEA serves as the precursor for both testosterone and estrogen synthesis in peripheral tissues including muscle. Low DHEA-S correlates with lower muscle mass, higher frailty scores, and increased mortality in observational studies. DHEA supplementation RCTs show modest but significant effects on lean mass and physical function in men and women with documented DHEA-S deficiency (Nair 2006, NEJM — 2 years DHEA 50mg daily increased leg strength and Tinetti balance score).

Omega-3 Fatty Acids and the Anti-Inflammatory Approach to Muscle Preservation

Chronic low-grade inflammation — “inflammaging” — drives muscle catabolism through NFκB activation, ubiquitin-proteasome pathway upregulation, and myofibrillar protein degradation. TNF-α (elevated in sarcopenic individuals) directly activates muscle protein breakdown independent of inactivity. Reducing inflammaging through dietary and supplemental omega-3 fatty acids is therefore a mechanistically coherent anti-sarcopenia strategy.

Smith et al. (2011, American Journal of Clinical Nutrition) conducted a landmark RCT of omega-3 supplementation (4g/day Lovaza-brand EPA/DHA) vs corn oil placebo in healthy older adults. After 8 weeks, omega-3 supplementation significantly amplified the MPS response to a euaminoacidemic-hyperinsulinemic clamp — suggesting that EPA/DHA directly sensitize muscle to anabolic stimuli, attenuating anabolic resistance. The mechanism involves EPA/DHA incorporation into muscle cell membrane phospholipids, improving insulin receptor and IGF-1 receptor signaling through enhanced membrane fluidity and lipid raft composition.

Lalia et al. (2017, Nutrients) supplemented 60 healthy older adults with 3.9g EPA/DHA daily x16 weeks alongside resistance training, finding significantly greater lean mass gain (+0.35 kg vs -0.07 kg placebo) and muscle strength improvement compared to resistance training with placebo — confirming the synergistic effect of omega-3 and exercise on muscle anabolism in older adults. Optimal dosing for muscle preservation: 3–4g combined EPA/DHA daily, ideally as 2g EPA + 2g DHA or comparable EPA-enriched formulations.

The Gut-Muscle Axis

Emerging evidence establishes a bidirectional “gut-muscle axis” that connects microbiome composition to muscle mass, strength, and function through multiple pathways. Germ-free animal studies demonstrate that absence of gut microbiota produces a sarcopenic phenotype — reduced muscle mass, fiber size, and grip strength — that reverses upon colonization with Bifidobacterium longum or Lactobacillus rhamnosus.

The mechanisms connecting gut microbiome to muscle are multifactorial: short-chain fatty acids (SCFAs) from microbial fermentation activate GPR41/43 receptors on muscle cells, promoting glucose uptake and mitochondrial biogenesis; butyrate specifically activates the mTOR-S6K1 pathway in muscle, directly stimulating MPS; tryptophan-derived indoles from microbiome metabolism reduce systemic inflammation and oxidative stress in muscle; and secondary bile acid metabolism by gut bacteria regulates FXR/TGR5 signaling that influences muscle mitochondrial function.

Gut microbiome diversity decreases with aging — and the specific losses parallel sarcopenia development: reduced Faecalibacterium prausnitzii (anti-inflammatory, butyrate-producing), reduced Bifidobacterium species (anabolic signaling through SCFA production), and increased pro-inflammatory Proteobacteria correlate with lower muscle mass in older adults across multiple cross-sectional studies. Dahl et al. (2024) demonstrated that probiotic supplementation with Lactobacillus fermentum CECT5716 in sarcopenic older adults produced significant improvement in appendicular lean mass index compared to placebo over 13 weeks — the first RCT evidence for probiotics as a direct sarcopenia intervention.

Functional Sarcopenia Assessment

Comprehensive functional assessment of sarcopenia risk combines body composition, functional performance, and underlying driver identification:

Body composition: DEXA scan — gold standard for appendicular lean mass index (ALMI), fat mass, and visceral fat assessment. Bioelectrical impedance analysis (BIA) provides a practical alternative; phase angle (a BIA-derived marker of cell membrane integrity) is an independent predictor of muscle quality beyond mass alone. Grip strength dynamometry: simple, highly predictive — low grip strength is the single best functional marker of sarcopenia risk.

Physical performance: Gait speed (4-meter or 6-meter walk test; <0.8 m/s indicates probable sarcopenia); SPPB (Short Physical Performance Battery — balance, 4-meter walk, 5 chair stands; score <8/12 indicates poor physical performance); 30-second chair stand test; Timed Up and Go (TUG) test (>12 seconds = functional limitation).

Biomarkers: IGF-1 (below 100 ng/mL increases sarcopenia risk), testosterone/free testosterone (in men: below 300 ng/dL total testosterone warrants clinical attention; in women: below 25 ng/dL free testosterone), DHEA-S (age-adjusted reference ranges; supplementation considered below lower quartile for age), serum 25(OH)D (target >50 ng/mL), hs-CRP and IL-6 (elevated inflammaging markers drive catabolism), ferritin (iron deficiency impairs mitochondrial biogenesis), albumin and pre-albumin (nutritional status and acute-phase markers).

Functional nutrition assessment: 3-day food diary analysis for total protein intake, protein distribution per meal, leucine content per meal, and total caloric adequacy — since many sarcopenic older adults are simultaneously hyperphagic with poor protein quality or hypocaloric, both conditions driving catabolism.

The Integrated Sarcopenia Prevention and Reversal Protocol

Six pillars for comprehensive muscle preservation across the lifespan:

Pillar 1 — Resistance training: 2–3 sessions weekly, all major muscle groups, progressive overload, RPE 6–8/10. Add high-velocity training for power. Consider BFR training for joint-limited individuals. This is the irreplaceable foundation — no supplementation substitutes for mechanical loading.

Pillar 2 — Protein optimization: 1.2–1.6g protein/kg body weight/day, distributed across 3–4 meals providing 25–40g per meal, each exceeding 2.5–3g leucine. Prioritize leucine-rich sources (whey, eggs, meat, fish). Consume protein within 0–2 hours post-resistance training to maximize post-exercise MPS.

Pillar 3 — Key supplements: Creatine monohydrate 3–5g daily (most evidence-based, especially with resistance training); omega-3 EPA/DHA 3–4g daily (reduces inflammaging, sensitizes muscle to anabolic stimuli); vitamin D3 to serum target 50–80 ng/mL; beta-hydroxy beta-methylbutyrate (HMB) 3g daily — an active leucine metabolite with specific anti-proteolytic effects in older adults (Wilson 2014, JCEM — HMB-FA 3g + vitamin D 2000 IU significantly increased lean mass +7.6% and reduced fat mass in 12-month RCT of older adults).

Pillar 4 — Hormonal optimization: Testosterone replacement in documented hypogonadism (TRT in men <300 ng/dL total T with symptoms; DHEA 10–25mg in women with documented DHEA-S below age-appropriate reference range); DHEA 25–50mg in older adults with documented deficiency; Vitamin D as above; IGF-1 stimulation through peptides (sermorelin, CJC-1295) for documented GH axis decline. Under appropriate medical supervision.

Pillar 5 — Anti-inflammaging: Mediterranean dietary pattern (reduces TNF-α, IL-6 — which drive muscle catabolism); omega-3 3–4g; curcumin 500mg twice daily (bioavailable formulations: phytosome or nanoparticle); quercetin 500mg; and treatment of underlying inflammatory conditions (periodontal disease, NAFLD, insulin resistance, chronic sleep deprivation) that maintain elevated inflammatory cytokines.

Pillar 6 — Gut-muscle axis: Diverse plant-based diet (30+ plant species weekly for microbiome diversity), fermented foods daily (kefir, yogurt, kimchi), prebiotic fiber (FOS, inulin, resistant starch) feeding SCFA-producing species; targeted probiotic supplementation (Lactobacillus rhamnosus, Bifidobacterium longum for documented dysbiosis); adequate dietary protein reaching the colon (1.2–1.5g/kg body weight/day leaves sufficient protein for colonic fermentation by microbiota).

Frequently Asked Questions About Sarcopenia

Is it too late to build muscle after 70?

No. The Fiatarone 1990 JAMA study demonstrated 113% strength gains in nursing home residents averaging 87 years through 8 weeks of resistance training. While absolute hypertrophy rates are lower than in young adults, older adults respond to progressive resistance training with meaningful strength and lean mass increases at any age — the neuromuscular system retains plasticity across the lifespan. Even 4–6 weeks of resistance training in previously sedentary older adults produces functional improvements (chair stand speed, stair climbing, balance) that translate to reduced fall risk.

Can you build muscle on a plant-based diet?

Yes, but it requires more nutritional attention. Plant proteins are generally less leucine-rich and less bioavailable than animal proteins, requiring higher total protein intake (approximately 10–15% more) to achieve equivalent leucine delivery. Key strategies: combine rice + pea protein for a complete amino acid profile matching whey; add free leucine (2–5g) to plant protein meals; increase total protein intake to 1.4–1.8g/kg; rely on soy protein as the most complete plant source; and consider creatine supplementation (creatine is found exclusively in animal products — vegans have measurably lower muscle creatine stores and show the largest performance improvements with supplementation).

How much protein do you actually need per meal to build muscle?

The leucine threshold — not total protein — drives MPS. For young adults: approximately 20–25g of high-quality protein (2.5g leucine) maximally stimulates MPS per meal. For older adults: 35–45g of high-quality protein (3–4g leucine) due to anabolic resistance. Additional protein above this threshold per meal does not further stimulate MPS acutely but contributes to total daily amino acid pool. The practical recommendation: 30–40g protein at breakfast, lunch, and dinner rather than the typical American pattern of minimal protein at breakfast and lunch with most protein at dinner.

Sarcopenia is the silent epidemic of aging — clinically underdiagnosed, inadequately treated, and incorrectly accepted as inevitable. Muscle mass preservation is among the most evidence-dense interventions available in functional longevity medicine, with RCT support across protein optimization, resistance training, creatine, omega-3 fatty acids, vitamin D, hormonal optimization, and microbiome support. If you are concerned about muscle loss with aging, or want comprehensive body composition assessment and a personalized sarcopenia prevention protocol, contact The Private Practice at (810) 206-1402 to schedule a consultation.